𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A double-blind placebo-controlled study of auranofin in patients with psoriatic arthritis

✍ Scribed by Simon Carette; Andrei Calin; Jim P. McCafferty; Bruce A. Wallin

Publisher
John Wiley and Sons
Year
1989
Tongue
English
Weight
759 KB
Volume
32
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A double-blind, placebo-controlled study
A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis
✍ Nancy J. Olsen; Raye H. Brooks; John J. Cush; Peter E. Lipsky; E. William St. Cl πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 654 KB

Objective. To evaluate the efficacy of an antLCD5 ricin-linked immunoconjugate (CD5-IC) in patients with rheumatoid arthritis (RA). Methods. A total of 104 evaluable patients were enrolled in a multicenter, double-blind, multiple-dose, placebo-controlled study of CDS-IC. Results. Treatment with CD

Alefacept in combination with methotrexa
Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: Results of a randomized, double-blind, placebo-controlled study
✍ Philip J. Mease; Dafna D. Gladman; Edward C. Keystone πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 165 KB πŸ‘ 2 views

## Abstract ## Objective To evaluate the efficacy and safety of alefacept in combination with methotrexate (MTX) for the treatment of psoriatic arthritis (PsA). ## Methods Patients were eligible for this randomized, double‐blind, placebo‐controlled trial if they were ages 18–70 years and had act

Effects of tumor necrosis factor blockad
Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double-blind, placebo-controlled study
✍ Naveed Sattar; Philippa Crompton; Lynne Cherry; David Kane; Gordon Lowe; Iain B. πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 110 KB

## Abstract ## Objective To conduct a robust, double‐blind, placebo‐controlled study examining the effects of tumor necrosis factor (TNF) modulation on concentrations of traditional and novel cardiovascular disease risk factors in patients with an inflammatory condition. ## Methods In this doubl